Remote monitoring via Satelia® LVAD was feasible with 79% compliance, detecting 9,878 hospitalization risk alerts and resolving nearly half, mainly cardiac decompensation.
Does remote monitoring via a web application facilitate follow-up and detect hospitalization risk alerts in LVAD patients?
Remote monitoring via a dedicated web application is feasible for LVAD patients, demonstrating high compliance and the ability to detect hospitalization risk alerts.
Abstract Background Left-ventricular assist devices (LVADs) are a major therapeutic option for advanced heart failure (adHF) patients as both destination or bridge to transplant therapy (BTT). LVAD has been reported to improve patient’s survival and quality of life (QoL), but complications can alter their prognosis. Specialized remote monitoring may facilitate LVAD’s patient’s follow-up and improve their outcomes. Aims To describe and evaluate the usefulness of remote monitoring for LVAD patients. Methods A national retrospective study was conducted at nine tertiary hospitals. LVAD patients that were followed-up with a web application (Satelia® LVAD) were included. Data collected involved patient and medical characteristics, and detected hospitalization risk alerts. Results In total, 161 patients were included (male=82.0%, mean age=62.2 years). Indications for LVAD were mainly ischemic cardiomyopathy (82.0%) and BTT (50.3%). The mean follow-up duration lasted 19.9 1,45 months with 76 (47.2%) patients continuing remote monitoring. Compliance to remote monitoring was relatively high (79.0%). The main reason for cessation was death (30.6%). Total hospitalization risk alerts detected by remote monitoring were: orange alerts (n=8,265, 72.3%) and red alerts (n=1,613, 14.1%) with 48.5% of cases resolved (orange=50.8% vs red=54.8%). The most frequent type of resolved alert was for a measured risk of cardiac decompensation (orange=2,227 vs red=382). Conclusion To our knowledge, this is the first extensive study to describe the follow-up of LVAD patients by dedicated remote monitoring program. Remote monitoring as a specific follow-up tool may be feasible for this sub population. Future randomized studies on specific prospective evaluations such as survival and QoL are needed.
Delmas et al. (2025) studied this question. Remote monitoring via Satelia® LVAD was feasible with 79% compliance, detecting 9,878 hospitalization risk alerts and resolving nearly half, mainly cardiac decompensation.